EPS for Medicure Inc. (MPH) Expected At $0.12

November 10, 2018 - By Alfred Lee

Analysts expect Medicure Inc. (CVE:MPH) to report $0.12 EPS on November, 20.They anticipate $0.06 EPS change or 100.00 % from last quarter’s $0.06 EPS. V_MPH’s profit would be $1.89M giving it 12.88 P/E if the $0.12 EPS is correct. After having $0.09 EPS previously, Medicure Inc.’s analysts see 33.33 % EPS growth. The stock decreased 1.90% or $0.12 during the last trading session, reaching $6.18. About 11,583 shares traded or 122.24% up from the average. Medicure Inc. (CVE:MPH) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Medicure Inc., a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company has market cap of $97.11 million. The firm primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It has a 2.23 P/E ratio. It is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.